The Role of Atrial Fibrosis Detected by Delayed - Enhancement MRI in Atrial Fibrillation Ablation

Author(s): Zsuzsanna Kis, Astrid Amanda Hendriks, Taulant Muka, Wichor M. Bramer, Istvan Kovacs, Tamas Szili-Torok*

Journal Name: Current Medical Imaging
Formerly: Current Medical Imaging Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Atrial Fibrillation (AF) is associated with remodeling of the atrial tissue, which leads to fibrosis that can contribute to the initiation and maintenance of AF. Delayed- Enhanced Cardiac Magnetic Resonance (DE-CMR) imaging for atrial wall fibrosis detection was used in several studies to guide AF ablation. The aim of present study was to systematically review the literature on the role of atrial fibrosis detected by DE-CMR imaging on AF ablation outcome.

Methods: Eight bibliographic electronic databases were searched to identify all published relevant studies until 21st of March, 2016. Search of the scientific literature was performed for studies describing DE-CMR imaging on atrial fibrosis in AF patients underwent Pulmonary Vein Isolation (PVI).

Results: Of the 763 citations reviewed for eligibility, 5 articles (enrolling a total of 1040 patients) were included into the final analysis. The overall recurrence of AF ranged from 24.4 - 40.9% with median follow-up of 324 to 540 days after PVI. With less than 5-10% fibrosis in the atrial wall there was a maximum of 10% recurrence of AF after ablation. With more than 35% fibrosis in the atrial wall there was 86% recurrence of AF after ablation.

Conclusion: Our analysis suggests that more extensive left atrial wall fibrosis prior ablation predicts the higher arrhythmia recurrence rate after PVI. The DE-CMR imaging modality seems to be a useful method for identifying the ideal candidate for catheter ablation. Our findings encourage wider usage of DE-CMR in distinct AF patients in a pre-ablation setting.

Keywords: Atrial fibrillation, delayed-enhancement cardiac MRI, atrial fibrosis, catheter ablation, outcome of ablation, follow-up.

[1]
Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14(4): 528-606.
[http://dx.doi.org/10.1093/europace/eus027] [PMID: 22389422]
[2]
Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the heart rhythm society. Europace 2006; 8(9): 651-745.
[PMID: 16987906]
[3]
Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace 2015; 17(3): 370-8.
[http://dx.doi.org/10.1093/europace/euu376] [PMID: 25643988]
[4]
Morillo CA, Verma A, Connolly SJ, et al. RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014; 311(7): 692-700.
[http://dx.doi.org/10.1001/jama.2014.467] [PMID: 24549549]
[5]
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293(21): 2634-40.
[http://dx.doi.org/10.1001/jama.293.21.2634] [PMID: 15928285]
[6]
Camm AJ, Lip GY, De Caterina R, et al. ESC committee for practice guidelines-CPG; document reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation--developed with the special contribution of the European heart rhythm association. Europace 2012; 14(10): 1385-413.
[http://dx.doi.org/10.1093/europace/eus305] [PMID: 22923145]
[7]
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339(10): 659-66.
[http://dx.doi.org/10.1056/NEJM199809033391003] [PMID: 9725923]
[8]
Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109(3): 327-34.
[http://dx.doi.org/10.1161/01.CIR.0000112641.16340.C7] [PMID: 14707026]
[9]
Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2013; 2(2)e004549
[http://dx.doi.org/10.1161/JAHA.112.004549] [PMID: 23537812]
[10]
Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96(9): 3157-63.
[http://dx.doi.org/10.1161/01.CIR.96.9.3157] [PMID: 9386188]
[11]
Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kühlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44(1): 121-31.
[http://dx.doi.org/10.1016/S0008-6363(99)00178-9] [PMID: 10615396]
[12]
Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54(2): 230-46.
[http://dx.doi.org/10.1016/S0008-6363(02)00258-4] [PMID: 12062329]
[13]
Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008; 51(1): 1-11.
[http://dx.doi.org/10.1016/j.jacc.2007.09.026] [PMID: 18174029]
[14]
Akoum N, Daccarett M, McGann C, et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol 2011; 22(1): 16-22.
[http://dx.doi.org/10.1111/j.1540-8167.2010.01876.x] [PMID: 20807271]
[15]
Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009; 119(13): 1758-67.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.811877] [PMID: 19307477]
[16]
Mahnkopf C, Badger TJ, Burgon NS, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 2010; 7(10): 1475-81.
[http://dx.doi.org/10.1016/j.hrthm.2010.06.030] [PMID: 20601148]
[17]
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014; 311(5): 498-506.
[http://dx.doi.org/10.1001/jama.2014.3] [PMID: 24496537]
[18]
Akoum N, Morris A, Perry D, et al. Substrate modification is a better predictor of catheter ablation success in atrial fibrillation than pulmonary vein isolation: An LGE-MRI study. Clin Med Insights Cardiol 2015; 9: 25-31.
[http://dx.doi.org/10.4137/CMC.S22100] [PMID: 25983561]
[19]
Canpolat U, Oto A, Hazirolan T, et al. A prospective DE-MRI study evaluating the role of TGF-β1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy. J Cardiovasc Electrophysiol 2015; 26(3): 251-9.
[http://dx.doi.org/10.1111/jce.12578] [PMID: 25366936]
[20]
Khurram IM, Habibi M, Gucuk Ipek E, et al. Left atrial LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and persistent AF. JACC Cardiovasc Imaging 2016; 9(2): 142-8.
[http://dx.doi.org/10.1016/j.jcmg.2015.10.015] [PMID: 26777218]
[21]
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343(20): 1445-53.
[http://dx.doi.org/10.1056/NEJM200011163432003] [PMID: 11078769]
[22]
Akoum N, Wilber D, Hindricks G, et al. MRI assessment of ablation-induced scarring in atrial fibrillation: analysis from the DECAAF study. J Cardiovasc Electrophysiol 2015; 26(5): 473-80.
[http://dx.doi.org/10.1111/jce.12650] [PMID: 25727106]
[23]
Kowalski M, Grimes MM, Perez FJ, et al. Histopathologic characterization of chronic radiofrequency ablation lesions for pulmonary vein isolation. J Am Coll Cardiol 2012; 59(10): 930-8.
[http://dx.doi.org/10.1016/j.jacc.2011.09.076] [PMID: 22381429]
[24]
Badger TJ, Daccarett M, Akoum NW, et al. Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement MRI in repeat ablation procedures. Circ Arrhythm Electrophysiol 2010; 3(3): 249-59.
[http://dx.doi.org/10.1161/CIRCEP.109.868356] [PMID: 20335558]
[25]
Narayan SM, Krummen DE, Clopton P, Shivkumar K, Miller JM. Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM trial (Conventional ablation for AF with or without focal impulse and rotor modulation). J Am Coll Cardiol 2013; 62(2): 138-47.
[http://dx.doi.org/10.1016/j.jacc.2013.03.021] [PMID: 23563126]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [135 - 144]
Pages: 10
DOI: 10.2174/1573405614666180806130327
Price: $65

Article Metrics

PDF: 23
HTML: 5